[Skip to Content]
[Skip to Content Landing]
Comment & Response
November 2016

Rebound Syndrome in Multiple Sclerosis After Fingolimod Cessation—Reply

Author Affiliations
  • 1Department of Neurology, University of California, San Francisco
JAMA Neurol. 2016;73(11):1376. doi:10.1001/jamaneurol.2016.3202

In Reply We thank Merschhemke et al and Andrade for their interest in our article.1 We appreciate Merschhemke et al highlighting that data have been collected on patients participating in fingolimod trials for up to 3 months after drug cessation. However, these data have not, to our knowledge, been subjected to the peer-review process and published and, as such, were not available for our review when writing up our cases.